Tvardi Therapeutics, Inc. (TVRD)
0.8571
-0.01
(-0.86%)
USD |
NASDAQ |
Nov 06, 10:42
Tvardi Therapeutics Net Income (Quarterly) : -6.457M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -6.457M |
| March 31, 2026 | -6.804M |
| December 31, 2025 | -7.275M |
| September 30, 2025 | -5.527M |
| June 30, 2025 | 4.167M |
| March 31, 2025 | -9.579M |
| December 31, 2024 | -12.71M |
| September 30, 2024 | -5.513M |
| June 30, 2024 | -6.975M |
| March 31, 2024 | -30.70M |
| December 31, 2023 | -32.34M |
| September 30, 2023 | -28.03M |
| June 30, 2023 | -31.48M |
| March 31, 2023 | -26.66M |
| December 31, 2022 | -30.34M |
| September 30, 2022 | -23.18M |
| June 30, 2022 | -4.206M |
| March 31, 2022 | -27.75M |
| December 31, 2021 | -33.38M |
| September 30, 2021 | -1.013M |
| June 30, 2021 | -30.74M |
| March 31, 2021 | -23.30M |
| December 31, 2020 | 78.91M |
| September 30, 2020 | -16.51M |
| June 30, 2020 | -25.07M |
| Date | Value |
|---|---|
| March 31, 2020 | -28.92M |
| December 31, 2019 | -28.61M |
| September 30, 2019 | -32.84M |
| June 30, 2019 | -22.96M |
| March 31, 2019 | -21.96M |
| December 31, 2018 | -20.65M |
| September 30, 2018 | -19.40M |
| June 30, 2018 | -17.19M |
| March 31, 2018 | -16.77M |
| December 31, 2017 | -14.18M |
| September 30, 2017 | -12.44M |
| June 30, 2017 | -9.30M |
| March 31, 2017 | -22.20M |
| December 31, 2016 | -21.97M |
| September 30, 2016 | -11.54M |
| June 30, 2016 | -13.08M |
| March 31, 2016 | -10.69M |
| December 31, 2015 | -9.53M |
| September 30, 2015 | -4.787M |
| June 30, 2015 | -5.684M |
| March 31, 2015 | -4.689M |
| December 31, 2014 | -4.172M |
| September 30, 2014 | -6.545M |
| June 30, 2014 | -3.645M |
| March 31, 2014 | -3.383M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 124.49M |
| Veru, Inc. | -6.988M |
| Johnson & Johnson | 210.00M |
| Eli Lilly & Co. | 6.451B |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 6.457M |
| EPS Diluted (Quarterly) | -0.6883 |
| Enterprise Value | -7.510M |
| Earnings Yield | -324.2% |
| Normalized Earnings Yield | -324.17 |